Ocular Therapeutix, Inc. provided revenue guidance for the full year 2022. For the year, the company expected total net product revenue to be in the range of $55 million to $60 million, representing growth of between 26% to 38% over 2021. The growth is anticipated to be primarily driven by sales of DEXTENZA for the treatment of post-surgical inflammation and pain.